Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2011-08-30
2011-08-30
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S141100, C424S155100, C424S174100, C424S182100, C424S001490
Reexamination Certificate
active
08007797
ABSTRACT:
The present invention relates to the use of a compound that specifically binds to JAM-C or JAM-B for the treatment of gliomas. More specifically the invention relates to the use of an antagonist of JAM-B or JAM-C for the treatment of glioma, in particular astrocytoma.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5624659 (1997-04-01), Bigner et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5712120 (1998-01-01), Rodriguez et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 6399763 (2002-06-01), Frenken et al.
patent: 6469155 (2002-10-01), Fiume et al.
patent: 6635468 (2003-10-01), Ashkenazi et al.
patent: 6930172 (2005-08-01), Ferrara et al.
patent: 7393651 (2008-07-01), Imhof et al.
patent: 7642341 (2010-01-01), Imhof et al.
patent: 7670826 (2010-03-01), Imhof et al.
patent: 7790863 (2010-09-01), Imhof et al.
patent: 2003/0017534 (2003-01-01), Buelow et al.
patent: 2003/0073149 (2003-04-01), Archer et al.
patent: 2004/0208873 (2004-10-01), Teeling et al.
patent: 2005/0136060 (2005-06-01), Imhof et al.
patent: 2005/0266426 (2005-12-01), Imhof et al.
patent: 2007/0202110 (2007-08-01), Imhof et al.
patent: 2010/0267649 (2010-10-01), Imhof et al.
patent: 2010/0279307 (2010-11-01), Imhof et al.
patent: 0843961 (1996-05-01), None
patent: 1533617 (2005-05-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/22645 (1992-12-01), None
patent: WO 93/01227 (1993-01-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 95/35374 (1995-12-01), None
patent: WO 97/07671 (1997-03-01), None
patent: WO 98/24897 (1998-06-01), None
patent: WO 98/42739 (1998-10-01), None
patent: WO 99/06551 (1999-02-01), None
patent: WO 98/24884 (1999-06-01), None
patent: WO 99/45962 (1999-09-01), None
patent: WO 00/36102 (2000-06-01), None
patent: WO 00/53749 (2000-09-01), None
patent: WO 01/14404 (2001-03-01), None
patent: WO 01/14424 (2001-03-01), None
patent: WO 02/43478 (2002-06-01), None
patent: WO 03/006673 (2003-01-01), None
patent: WO 03/008541 (2003-01-01), None
patent: WO 03/059282 (2003-07-01), None
patent: WO 2004/055056 (2004-07-01), None
patent: WO 2005/050213 (2005-06-01), None
patent: WO 2006/084078 (2006-08-01), None
Allgayer, H. et al., “Activation of Src Kinase in Primary Colorectal Carcinoma”,Cancer, Jan. 15, 2002, pp. 344-351, vol. 94, No. 2.
Arrate, M.P. et al., “Cloning of Human Junctional Adhesion Molecule 3 (JAM3) and its Identification as the JAM2 Counter-receptor”,The Journal of Biological Chemistry, Dec. 7, 2001, pp. 45826-45832, vol. 276, No. 49.
Aurrand-Lions, M. et al., “JAM-2, a Novel Immunoglobulin Superfamily Molecule, Expressed by Endothelial and Lymphatic Cells”,The Journal of Biological Chemistry, Jan. 26, 2001, pp. 2733-2741, vol. 276, No. 4.
Aurrand-Lions, M. et al., “Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members”,Blood, Dec. 15, 2001, pp. 3699-3707, vol. 98, No. 13.
Ausman, J.I. et al., “Studies on the Chemotherapy of Experimental Brain Tumors: Development of an Experimental Model”,Cancer Research, Sep. 1970, pp. 2394-2400, vol. 30.
Bendell, J.C. et al. “Central Nervous System Metastases in Women who Receive Trastuzumab-Based Therapy for Metastatic Breast Carcinoma”,Cancer, Jun. 15, 2003, pp. 2972-2977, vol. 97, No. 12.
Binz, H.K. et al., “High-affinity binders selected from designed ankyrin repeat protein libraries”,Nature Biotechnology, May 2004, pp. 575-582, vol. 22, No. 5, Nature Publishing Group.
Bitonti, A.J. et al., “Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway”,Advanced Drug Delivery Reviews, 2006, pp. 1106-1118, vol. 58, Elsevier B.V.
Bitonti, A.J. et al., “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway”,Proc. Natl. Acad. Sci. USA, Jun. 29, 2004, pp. 9763-9768, vol. 101, No. 26.
Chavakis, T. et al., “The Junctional Adhesion Molecule-C Promotes Neutrophil Transendothelial Migration in Vitro and in Vivo”,The Journal of Biological Chemistry, Dec. 31, 2004, pp. 55602-55608, vol. 279, No. 53.
Cunningham, S.A. et al., “A Novel Protein with Homology to the Junctional Adhesion Molecule”,The Journal of Biological Chemistry, Nov. 3, 2000, pp. 34750-34756, vol. 275, No. 44.
Dall'Acqua, W.F. et al., “Antibody humanization by framework shuffling”,Methods, 2005, pp. 43-60, vol. 36, Elsevier Inc.
Dall'Acqua, W.F. et al., “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences”,The Journal of Immunology, 2002, pp. 5171-5180, vol. 169.
Damschroder, M.M. et al., “Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties”,Molecular Immunology, 2007, pp. 3049-3060, vol. 44, Elsevier Ltd.
Datta-Mannan, A. et al., “Humanized IgG1Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates”,Drug Metabolism and Disposition, 2007, pp. 86-94, vol. 35, No. 1.
Datta-Mannan, A. et al., “Monoclonal Antibody Clearance: Impact of Modulating the Interaction of IgG with the Neonatal Fc Receptor”,The Journal of Biological Chemistry, Jan. 19, 2007, pp. 1709-1717, vol. 282, No. 3.
Dufner, P. et al., “Harnessing phage and ribosome display for antibody optimisation”,TRENDS in Biotechnology, 2006, pp. 523-529, vol. 24, No. 11, Elsevier Ltd.
Dumont, J.A. et al., “Delivery of an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway”,Journal of Aerosol Medicine, 2005, pp. 294-303, vol. 18, No. 3.
Edelman, G.M. et al., “The Covalent Structure of an Entire γG Immunoglobulin Molecule”,Biochemistry, 1969, pp. 78-85, vol. 63.
Gerber, D.E. et al., “Emerging monoclonal antibody therapies for malignant gliomas”,Expert Opin. Investig. Drugs, 2007, pp. 477-494, vol. 16, No. 4, Informa UK Ltd.
Ghetie, V. et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis”,Nature Biotechnology, Jul. 1997, pp. 637-640, vol. 15, Nature Publishing Group.
Gill, D.S et al., “Biopharmaceutical drug discovery using novel protein scaffolds”,Current Opinion in Biotechnology, 2006, pp. 653-658, vol. 17, Elsevier Ltd.
Gonzales, N. R. et al., “SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity”,Molecular Immunology, 2004, pp. 863-872, vol. 41, Elsevier Ltd.
Green, L.L., “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies”,Journal of Immunological Methods, 1999, pp. 11-23, vol. 231, Elsevier Science B.V.
Groves, M.A.T. et al., “Applications of ribosome display to antibody drug discovery”,Expert Opin. Biol. Ther., 2005, pp. 125-135, vol. 5, No. 1, Ashley Publications.
Hinton, P.R. et al., “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates”,The Journal of Biological Chemistry, Feb. 20, 2004, pp. 6213-6216, vol. 279, No. 8.
Hinton, P.R. et al., “An Engineered Human IgG1 Antibody with Longer Serum Half-Life”,The Journal of Immunology, 2006, pp. 346-356, vol. 176.
Holliger, P. and Hudson, P.J., “Engineered antibody fragments and the rise of single domains”,Nature Biotechnology, Sep. 2005, pp. 1126-1136, vol. 23, No. 9,
Aurrand-Lions Michel
Dietrich Pierre-Yves
Imhof Beat Albert
Tenan Mirna
Huff Sheela J
Merck Serono S.A.
Saliwanchik Lloyd & Eisenschenk
LandOfFree
Junctional adhesion molecule-C (JAM-C) binding compounds and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Junctional adhesion molecule-C (JAM-C) binding compounds and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Junctional adhesion molecule-C (JAM-C) binding compounds and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735681